Kaplan-Meier survival analysis of 875 patients with GC revealed that patients with high NLRP1/NLRP3 expression had worse overall survival (OS), first-progression survival (FPS), and post-progression survival (PPS); (Figure 3A–3C; NLRP1: OS, HR = 1.77, p = 2.3 × 10−10; FPS, HR = 1.76, p = 8.1 × 10−8; PPS, HR = 2.73, p = 1 × 10−16; Figure 3D–3F; NLRP3: OS, HR = 1.54, p = 1.1 × 10−6; FPS, HR = 1.59, p = 2.7 × 10−5; PPS, HR = 2.04, p = 1.9 × 10−9), suggesting that high expression of NLRP1/NLRP3 may be related to reduced survival in patients with GC. Here, NLRP1 is linked to gastric cancer.